THE PAX LC TRIAL

We’ve joined the race to find treatments. Kindred is working with Yale scientists to help speed research.

Thank you for your interest. The PAX LC trial is now closed and enrollment is complete.

PAX LC stands for A Decentralized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavirin Adult Participants with Long COVID

Join Kindred

This decentralized Phase 2, 1:1 randomized, double-blind research study will determine the efficacy, safety, and tolerability of 15 days of nirmatrelvir/ritonavir compared with placebo/ritonavir. The study is exploratory, though the prespecified hypothesis is that nirmatrelvir/ritonavir compared with placebo/ritonavir can improve general health status in participants with long COVID.

Note: After you have joined Kindred, you will be taken to the Kindred Home Page. If you reside in CT, NY or FL look for the PAX LC study in the “Available Studies” box on the right side of your page. Tap on PAX LC to get started. If PAX LC is not available to you yet (more US states may be added), you can also consider enrolling in the Yale LISTEN study available to anyone impacted by COVID.

How the study works

People are being recruited through Kindred with a screening assessment survey. Those that meet the initial criteria will be referred to the Yale PAX LC research team for final screening, consent and enrollment.

The trial will be enrolling 100 people, who were in good health prior to contracting long COVID. Initially, residents of Connecticut, New York and Florida are eligible, however recruitment will expand to other US residents.

The Yale School of Medicine is the coordinating center with leadership, oversight, and data analytic and laboratory tasks. Medications are distributed and biospecimens are collected at the convenience of trial; participants in their home.

The Yale PAX LC investigators have agreed to work in partnership with Kindred members throughout the trial, including sharing results back with participants when the analysis is complete. Participants are free to leave the study as well as the Hugo Health Kindred anytime. Please go here for information about how to unenroll.

Hugo Health Kindred is proud to work only with researchers who agree to Kindred’s Research Principles: treating participants as partners and with respect, listening to participant suggestions about the study, abiding by Hugo Health Kindred’s strict data use agreement, and engaging participants in interpreting and disseminating results.

“Progress requires teamwork, trust, and tenacity; and the courage to believe that anything is possible if we work together.”

— Dr. Harlan Krumholz, cardiologist and scientist at Yale University and Yale New Haven Hospital.

How to join the research study

The PAX LC trial is recruiting from the Hugo Kindred Community to rapidly enroll and partner with study participants. This method of recruitment has been approved by the Yale committee that oversees studies and protects the interests of participants. To get started, join Kindred. The study is enrolling now.

Kindred is a platform created by Hugo Health that allows people to connect to their health data and join research studies. As a diclosure, Dr. Harlan Krumholz, is the Principal investigator of the PAX LC study, is a co-founder of Hugo Health.

Learn more about Kindred.